Articles by George Koroneos - Pharmaceutical Executive


Articles by George Koroneos

Controlled-Release OxyContin Approved as Rx ODs Spike

Apr 7, 2010

FDA approves a new formulation of Purdue Pharma's notoriously addictive opioid. This version is supposed to make it harder for the drug to be repurposed for nefarious consumption.

GSK and Pfizer to Discount Pneumonia Vaccines for the Poor

Mar 24, 2010

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.

Emerging Markets to Account for Half of Market Growth by 2013

Mar 17, 2010

A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?

Rx Abandonment Rate Continues to Rise

Mar 17, 2010

The number of consumers ditching their drugs at the pharmacy keeps climbing as the economy worsens.

Ernst & Young Puts the Spotlight on Pharma 3.0

Feb 10, 2010

The blockbuster model has been dead for a while, but pharma is just now researching new ways to reach patients. Pharm Exec interviews Carolyn Luce at Ernst & Young to learn more about the new era of pharma outreach and marketing.

Strategy for Security

Jan 13, 2010

A new pharma consortium focuses on securing the supply chain upstream. Pharm Exec interviews Rx360 to learn more.

GSK Makes Physician Payments Public

Dec 16, 2009

Transparency can be a double-edged sword - especially if you are a doctor receiving money to speak on behalf of a drug company. Sure the pay day is nice, but does the public outing open you up to scrutiny?

Sanofi Gets a Bad Batch of H1N1 Vaccines

Dec 16, 2009

Sanofi-Aventis is recalling hundreds of thousands of doses of the childrens' version of its H1N1 vaccine. Conspiracy theorists are going to have a field day.

Gilead and Elan Struggle with Clinical Trials

Dec 16, 2009

It's been a tough week for clinical trials: One drug got canned and another was re-tuned in the wake of failed end points and patient deaths.


Click here